WO2007056460A2 - Treatment of length dependent neuropathy - Google Patents
Treatment of length dependent neuropathy Download PDFInfo
- Publication number
- WO2007056460A2 WO2007056460A2 PCT/US2006/043499 US2006043499W WO2007056460A2 WO 2007056460 A2 WO2007056460 A2 WO 2007056460A2 US 2006043499 W US2006043499 W US 2006043499W WO 2007056460 A2 WO2007056460 A2 WO 2007056460A2
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- clonidine
- chloro
- hydrogen
- treatment
- neuropathy
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/4168—1,3-Diazoles having a nitrogen attached in position 2, e.g. clonidine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/425—Thiazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
Definitions
- the invention is directed to the treatment of pain associated with length dependent and other neuropathies such as may result from diabetes and other conditions.
- diabetes mellitus Diabetes may affect the nervous system in different ways but one of the classical disorders is a length dependent neuropathy.
- the classic feature is burning pain typically involving the feet given that the axons to the feet represent the longest primary afferents in the body. This problem may occur early or late in the disease, and in fact may occur in so-called pre-diabetes which is a condition representing a disorder of glucose metabolism without strictly meeting the criteria for diabetes mellitus.
- diabetes is but one cause of a length dependent neuropathy.
- the painful symptoms that accompany these disorders, including an idiopathic small fiber neuropathy are nearly identical with that seen in diabetes mellitus.
- Treatments directed at treatment of the diabetes mellitus itself may help slow the progression of the neuropathy but do not necessarily address the pain.
- Certain chemotherapeutic drugs induce a length dependent neuropathy associated with pain. This pain may limit dosing and thus affect the adequacy of the cancer treatment.
- Systemic treatments of pain include use of opioids, anticonvulsants, antidepressants, and membrane stabilizers. All of these therapies are frequently ineffective and typically their use is accompanied by a substantial adverse side effect profile.
- Systemic therapies can be given by the oral route, or by patches applied to the skin.
- Lidocaine patches can be applied to the skin. Their value in treatment of pain associated with length dependent neuropathies is limited because of numbing of the skin.
- Capsaicin can be applied locally to the skin but application is associated with significant pain and the capsaicin destroys nociceptor function.
- Clonidine a potent ⁇ 2 -adrenergic partial agonist used primarily for the treatment of hypertension.
- Clonidine has been applied topically to areas remote to the painful area as an alternative to oral delivery for effecting systemic delivery. For example, in a placebo-controlled cross-over pain trial in patients with painful diabetic neuropathy, no statistically significant difference between patients receiving systemic clonidine administered with transdermal patches and patients receiving placebo patches was observed (Zeigler et al. Pain 48: 403-408 (1992)).
- transdermal patches delivering systemic levels of clonidine were evaluated using a two-stage enriched enrollment design (Byas-Smith et al. Pain 60: 261 -21 A (1995)). Only twelve of forty-one patients (29%) who completed the initial course of treatment were considered clonidine responders. These twelve clonidine responders were then rechallenged in a second placebo controlled study which used the highest dosage available with the transdermal patch system. The pain reduction relative to placebo tended to be modest although statistically significant (p ⁇ 0.015). The site of action of clonidine was not studied in this study. In principal the site of action could be central or peripheral.
- compositions, and methods of use thereof are provided for the treatment of pain due to length dependent or other neuropathy by local or topical delivery of concentrations of compounds that interact with ⁇ -2 adrenergic receptors, especially an alpha 2 adrenergic agonist such as clonidine, to the painful area, without producing systemically effective levels of the clonidine.
- the compounds are delivered to or adjacent to painful areas in patients with length dependent of other neuropathy that results in pain associated with disease or damage to the pain signaling primary afferent (sensory) fibers and their receptor, not sympathetically maintained pain.
- the alpha-2 agonist is topically applied to the feet in the painful region.
- a preferred compound for the treatment of patients with diabetic neuropathy is clonidine applied in an ointment, gel, lotion, or transdermal patch, wherein the dosage is sufficient to provide an effective dose in the painful area or immediately adjacent areas, preferably without producing pharmacologically active systemic blood levels.
- Figure 1 is a graph of pain score over time (1-9 weeks) that shows the mean NGPS reduction by week, diamond, 0.1% clonidine; square, 0.2% clonidine, and circle, placebo.
- Figure 2 is a graph of mean clonidine plasma concentratations over time from first dose (in days) of 0.1% clonidin for treatment A (dark circles): 3.15 g/day (3.1 mg clonidine HCl) and treatment B (open circles) 6.23 g/day (6.2 mg clonidine HCl).
- A. ⁇ 2 -adrenergic agonists The method of treating or reducing the symptoms (i.e. burning, pain) associated with length dependent neuropathies includes locally or topically administering an effective amount of an ⁇ 2 -adrenergic agonist or combination thereof.
- ⁇ 2 -adrenergic agonists are known to those skilled in the art. See, for example, The Pharmacological Basis of Therapeutics, 8th Edition, Gill, A. G., T. W. Rail, A. S. Nies, P. Taylor, editors (Pergamon Press, Co., Inc., NY 1990).
- Agents with alpha-2 adrenoreceptor agonist activity are represented by Formula I:
- a 4 may be selected from aryl, and heteroaryl, which may be substituted by one or more radicals selected from alkyl, branched alkyl, cycloalkyl, hydroxyl, alkoxy, cycloalkylalkyl, alkoxyalkyl, aryl, alkanoyl, alkoxycarbonyl, carboxyl, amino, cyano, halogen, thioalkyl, dialkylamino, arylamino, alkylsulfinyl, alkylsulfonyl, arylsulfinyl or arylsulfonyl; wherein X is selected from thio, imino, or methylene; wherein R 7 is selected from hydrogen, lower alkyl, or oxygen-containing heterocycle; and wherein n is either 2 or 3; or a pharmaceutically acceptable salt thereof.
- a preferred class of compounds of Formula I consists of those compounds wherein A 4 is phenyl; wherein A 4 is substituted phenyl, on which positions 2 and 6 of the phenyl ring may be independently substituted by a radical selected from hydrogen, chloro, methyl, ethyl, or cycloalkyl, and positions 3, 4, and 5 may be independently substituted by a radical selected from hydrogen, methyl, trifluoromethyl, fluoro, or cyano; wherein A 4 is 3- thienyl, on which positions 2 and 4 are independently substituted by a radical selected from hydrogen, chloro, methyl, ethyl, or cycloalkyl; wherein A 4 is 1-naphthyl, 5,6,7,8-tetrahydronaphthyl-l-yl, pyrrolyl, oxazolyl, isoxazolyl, indol-3-yl, indazol-3-yl, quinolinyl, quinazol
- An especially preferred class of compounds of Formula I consists of compounds wherein A 4 is selected from phenyl, 2,6-dichlorophenyl, 2,6- dimethylphenyl, 2,6-diethylphenyl, 3,4-dihydroxyphenyl, 3-fluoro-6- methylphenyl, 2-chloro-5-trifluoromethylphenyl, 2-chloro-4-methylphenyl, 3-chloro-4-methylthien-3-yl, 5,6,7,8-tetrahydronaphth-l-yl, and 4-chloro-5- methoxy-2-methylpyrimidin-4-yl; wherein R 7 is hydrogen or tetrahydropyran-2-yl; wherein X is thio or imino; and wherein n is 2.
- a specifically preferred class of compounds of Formula I consists of xylazine, flutonidine, moxonidine, tramazoline, tolonidine, piclonidine, tiamenidine, and clonidine.
- salts include, but are not limited to, mineral or organic acid salts of basic residues such as amines, and alkali or organic salts of acidic residues such as carboxylic acids.
- the pharmaceutically acceptable salts include the conventional non-toxic salts or the quaternary ammonium salts of the parent compound formed, for example, from non-toxic inorganic or organic acids.
- non-toxic salts include those derived from inorganic acids such as hydrochloric, hydrobromic, sulfuric, sulfamic, phosphoric and nitric acid ; and the salts prepared from organic acids such as acetic, propionic, succinic, glycolic, stearic, lactic, malic, tartaric, citric, ascorbic, pamoic, maleic, hydroxymaleic, phenylacetic, glutamic, benzoic, salicylic, sulfanilic, 2- acetoxybenzoic, fumaric, tolunesulfonic, methanesulfonic, ethane disulfonic, oxalic and isethionic acids.
- inorganic acids such as hydrochloric, hydrobromic, sulfuric, sulfamic, phosphoric and nitric acid
- organic acids such as acetic, propionic, succinic, glycolic, stearic, lactic, malic, tartaric, citric
- the pharmaceutically acceptable salts can be synthesized from the parent compound, which contains a basic or acidic moiety, by conventional chemical methods. Generally, such salts can be prepared by reacting the free acid or base forms of these compounds with a stoichiometric amount of the appropriate base or acid in water or in an organic solvent, or in a mixture of the two; generally, nonaqueous media like ether, ethyl acetate, ethanol, isopropanol, or acetonitrile are preferred. Lists of suitable salts are found in Remington 's Pharmaceutical Sciences, 17th ed. (Mack Publishing Company, Easton, PA, 1985, p. 1418).
- a prodrug is a covalently bonded substance which releases the active parent drug in vivo.
- Prodrugs are prepared by modifying functional groups present in the compound in such a way that the modifications are cleaved, either in routine manipulation or in vivo, to yield the parent compound.
- Prodrugs include compounds wherein the hydroxy or amino group is bonded to any group that, when the prodrug is administered to a mammalian subject, cleaves to form a free hydroxyl or free amino, respectively.
- Examples of prodrugs include, but are not limited to, acetate, formate and benzoate derivatives of alcohol and amine functional groups.
- a metabolite of the above-mentioned compounds results from biochemical processes by which living cells interact with the active parent drug or other formulas or compounds of the present invention in vivo. Metabolites include products or intermediates from any metabolic pathway.
- Topical administration is described for treatment of sympathetically maintained pain in U.S. Patent No. 5,447,947 issued September 5, 1995 to Campbell, and in U.S. Patent Nos. 6,534,048 issued March 18, 2003 to Borgman and 6,147,102 issued November 15, 2000 to Borgman. •
- the compounds are administered locally or topically directly to or adjacent the painful area, in a suitable pharmaceutical carrier, many of which are known to those skilled in the art.
- the carrier can be in the form of a lotion, ointment, gel, solution, or transdermal patch.
- Topical administration also includes iontophoresis wherein an electric current drives the drug, in the form of an ion such as a pharmaceutically acceptable salt, into the skin.
- the topical application allows the drug to reach high concentration at the painful area or tissue immediately adjacent thereto, avoiding many of the side effects of these compounds observed following systemic administration.
- the active compounds may be administered per se or in the form of a pharmaceutical composition wherein the active compound(s) is in admixture or mixture with one or more pharmaceutically acceptable carriers, excipients or diluents.
- Pharmaceutical compositions may be formulated in conventional manner using one or more physiologically acceptable carriers comprising excipients and auxiliaries which facilitate processing of the active compounds into preparations which can be used pharmaceutically.
- the dosage formulation can be administered alone or in combination with a therapy such as an opioid, anticonvulsant, membrane stabilizer, and/or psychoactive drugs (for example, anti-depressants).
- a therapy such as an opioid, anticonvulsant, membrane stabilizer, and/or psychoactive drugs (for example, anti-depressants).
- These may be formulated with the agonist in the pharmaceutically acceptable carrier for topical or local administration or administered in a separate formulation, with the other therapy being administered locally (by subcutaneous or intramuscular injection), topically or systemically, to the patient.
- neuropathies may also be caused by kidney disease, hormonal imbalances, vitamin deficiencies, alcoholism, autoimmune disorders, toxins, chemotherapy, and infections (e.g., AIDS).
- the treatment is given to patients with neuropathy that stems from diabetes mellitus.
- the treatment is administered to patients with a sensory peripheral neuropathy in the painful region.
- the treatment is administered to a patient with a small fiber neuropathy in the painful region.
- the dosage formulation is administered from once a week to several times a day, depending on the patient.
- the therapeutic agent is clonidine administered in a concentration between 0.1 and 10% clonidine.
- the dose is determined by the region of pain. Because the effect of the clonidine is local it must be applied to the painful area. Thus in patients with broader areas of pain a higher dose of clonidine will be necessary though the percent concentration remains constant.
- the area treated is constrained by the systemic dosing. When 0.5% clonidine is applied to both feet, systemic effects may emerge as blood levels will approach those observed in treatment of hypertension.
- the mean blood level was well below 0.1 ng/mg (one third of patients had no detectable clonidine in the blood), whereas the blood levels exceed 0.2 ng/ml with systemic delivery.
- Example 1 Formulation of NeuclonTM (clonidine) 0.1% Topical Gel NeuclonTM (clonidine) 0.1% Topical Gel contains 0.1 mg of clonidine hydrochloride per 1.0 gram gel. The gel is formulated at pH 8.0 in order to maximize the amount of clonidine freebase in the product. Clonidine hydrochloride has a pKa of 8.2. The formulation is shown in Table 1.
- Example 2 Treatment of patients with painful diabetic neuropathy
- the objective of this study was to test the analgesic effects of 0.1% and 0.2% topical clonidine gel compared to a placebo gel in patients with chronic, lower extremity, painful diabetic neuropathy.
- NGPS Numerical Graphic Pain Scale
- Figure 1 shows the mean NGPS reduction by week.
- Clonidine plasma concentration analysis in the group of six volunteers showed all samples to be below the limit of quantitation. Therefore, single doses, even as large as 2.0 mg/day of 0.1% topical clonidine gel are insufficiently absorbed to have any antihypertensive effect or be of any clinical consequence.
- the apparent dose-dependent pharmacokinetics with topical clonidine gel is of limited clinical importance in view of the substantially lower steady-state plasma concentrations as compared to those reported following clinically applicable doses of oral and transdermal clonidine.
- the mean C max of 0.067 ng/ml during treatment A and 0.181 ng/ml during treatment B are both below the threshold of clonidine plasma concentrations associated with the drug's antihypertensive effects (0.2 ng/ml). Additionally, no clinically important changes in blood pressure or heart rate occurred in any subjects during the study.
Landscapes
- Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Neurosurgery (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Engineering & Computer Science (AREA)
- Pain & Pain Management (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Oscillators With Electromechanical Resonators (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
Description
Claims
Priority Applications (12)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
DE602006019311T DE602006019311D1 (en) | 2005-11-08 | 2006-11-07 | TREATMENT OF LENGTH-DEPENDENT NEUROPATHY |
KR1020087011106A KR101389184B1 (en) | 2005-11-08 | 2006-11-07 | A dosage formulation for treatment of length dependent neuropathy |
PL06837161T PL1962836T3 (en) | 2005-11-08 | 2006-11-07 | Treatment of length dependent neuropathy |
AT06837161T ATE493128T1 (en) | 2005-11-08 | 2006-11-07 | TREATMENT OF LENGTH-DEPENDENT NEUROPATHY |
AU2006311580A AU2006311580B2 (en) | 2005-11-08 | 2006-11-07 | Treatment of length dependent neuropathy |
JP2008540162A JP5044566B2 (en) | 2005-11-08 | 2006-11-07 | Treatment of length-dependent neuropathy |
SI200630943T SI1962836T1 (en) | 2005-11-08 | 2006-11-07 | Treatment of length dependent neuropathy |
CA2628794A CA2628794C (en) | 2005-11-08 | 2006-11-07 | Treatment of length dependent neuropathy |
DK06837161.6T DK1962836T3 (en) | 2005-11-08 | 2006-11-07 | Treatment of length-dependent neuropathy |
EP06837161A EP1962836B1 (en) | 2005-11-08 | 2006-11-07 | Treatment of length dependent neuropathy |
HK09101396.9A HK1123501A1 (en) | 2005-11-08 | 2009-02-13 | Treatment of length dependent neuropathy |
AU2010214659A AU2010214659B2 (en) | 2005-11-08 | 2010-08-25 | Treatment of length dependent neuropathy |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US73442305P | 2005-11-08 | 2005-11-08 | |
US60/734,423 | 2005-11-08 |
Publications (2)
Publication Number | Publication Date |
---|---|
WO2007056460A2 true WO2007056460A2 (en) | 2007-05-18 |
WO2007056460A3 WO2007056460A3 (en) | 2007-08-23 |
Family
ID=37946498
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/US2006/043499 WO2007056460A2 (en) | 2005-11-08 | 2006-11-07 | Treatment of length dependent neuropathy |
Country Status (16)
Country | Link |
---|---|
EP (2) | EP1962836B1 (en) |
JP (2) | JP5044566B2 (en) |
KR (1) | KR101389184B1 (en) |
CN (2) | CN105147674A (en) |
AT (1) | ATE493128T1 (en) |
AU (2) | AU2006311580B2 (en) |
CA (1) | CA2628794C (en) |
CY (1) | CY1112190T1 (en) |
DE (1) | DE602006019311D1 (en) |
DK (1) | DK1962836T3 (en) |
ES (1) | ES2357033T3 (en) |
HK (1) | HK1123501A1 (en) |
PL (1) | PL1962836T3 (en) |
PT (1) | PT1962836E (en) |
SI (1) | SI1962836T1 (en) |
WO (1) | WO2007056460A2 (en) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2012012333A1 (en) * | 2010-07-19 | 2012-01-26 | Arcion Therapeutics, Inc. | Topical treatment of neuropathic pain and methods of diagnosis |
Families Citing this family (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN101947222A (en) * | 2010-08-18 | 2011-01-19 | 徐震 | Ointment for treating high blood pressure and preparation method thereof |
Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1992014453A1 (en) * | 1991-02-26 | 1992-09-03 | Arc 1, Inc. | Compositions and methods of treatment of sympathetically maintained pain |
US6054461A (en) * | 1997-09-16 | 2000-04-25 | Solvay Pharmaceuticals Gmbh | Treatment of neuropathic pain |
US6147102A (en) * | 1999-10-26 | 2000-11-14 | Curatek Pharmaceuticals Holding, Inc. | Clonidine preparations |
WO2007025613A2 (en) * | 2005-07-15 | 2007-03-08 | Laboratorios Del Dr. Esteve, S.A. | Use of compounds binding to the sigma receptor for the treatment of diabetes-associated pain |
Family Cites Families (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5447947A (en) | 1990-02-26 | 1995-09-05 | Arc 1 | Compositions and methods of treatment of sympathetically maintained pain |
US7687080B2 (en) * | 2002-11-25 | 2010-03-30 | Taraxos Inc. | Treatment of neuropathy |
-
2006
- 2006-11-07 CA CA2628794A patent/CA2628794C/en not_active Expired - Fee Related
- 2006-11-07 AT AT06837161T patent/ATE493128T1/en active
- 2006-11-07 CN CN201510491599.8A patent/CN105147674A/en active Pending
- 2006-11-07 SI SI200630943T patent/SI1962836T1/en unknown
- 2006-11-07 JP JP2008540162A patent/JP5044566B2/en not_active Expired - Fee Related
- 2006-11-07 AU AU2006311580A patent/AU2006311580B2/en not_active Ceased
- 2006-11-07 EP EP06837161A patent/EP1962836B1/en not_active Expired - Fee Related
- 2006-11-07 ES ES06837161T patent/ES2357033T3/en active Active
- 2006-11-07 PL PL06837161T patent/PL1962836T3/en unknown
- 2006-11-07 WO PCT/US2006/043499 patent/WO2007056460A2/en active Application Filing
- 2006-11-07 EP EP10173217A patent/EP2343068A3/en not_active Ceased
- 2006-11-07 DK DK06837161.6T patent/DK1962836T3/en active
- 2006-11-07 CN CNA2006800479611A patent/CN101365445A/en active Pending
- 2006-11-07 KR KR1020087011106A patent/KR101389184B1/en not_active IP Right Cessation
- 2006-11-07 DE DE602006019311T patent/DE602006019311D1/en active Active
- 2006-11-07 PT PT06837161T patent/PT1962836E/en unknown
-
2009
- 2009-02-13 HK HK09101396.9A patent/HK1123501A1/en not_active IP Right Cessation
-
2010
- 2010-08-25 AU AU2010214659A patent/AU2010214659B2/en not_active Ceased
-
2011
- 2011-03-15 CY CY20111100291T patent/CY1112190T1/en unknown
-
2012
- 2012-02-15 JP JP2012030574A patent/JP2012097121A/en not_active Withdrawn
Patent Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1992014453A1 (en) * | 1991-02-26 | 1992-09-03 | Arc 1, Inc. | Compositions and methods of treatment of sympathetically maintained pain |
US6054461A (en) * | 1997-09-16 | 2000-04-25 | Solvay Pharmaceuticals Gmbh | Treatment of neuropathic pain |
US6147102A (en) * | 1999-10-26 | 2000-11-14 | Curatek Pharmaceuticals Holding, Inc. | Clonidine preparations |
WO2007025613A2 (en) * | 2005-07-15 | 2007-03-08 | Laboratorios Del Dr. Esteve, S.A. | Use of compounds binding to the sigma receptor for the treatment of diabetes-associated pain |
Non-Patent Citations (1)
Title |
---|
D. ZEIGLER, S. A. LYNCH, J. MUIR, J. BENJAMIN, M. B. MAX: "Transdermal clonidine versus placebo in painful diabetic neuropathy" PAIN, vol. 48, 1992, pages 403-408, XP002435596 * |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2012012333A1 (en) * | 2010-07-19 | 2012-01-26 | Arcion Therapeutics, Inc. | Topical treatment of neuropathic pain and methods of diagnosis |
Also Published As
Publication number | Publication date |
---|---|
JP2009514970A (en) | 2009-04-09 |
ATE493128T1 (en) | 2011-01-15 |
DK1962836T3 (en) | 2011-02-28 |
AU2006311580B2 (en) | 2010-06-24 |
HK1123501A1 (en) | 2009-06-19 |
JP2012097121A (en) | 2012-05-24 |
CA2628794A1 (en) | 2007-05-18 |
CA2628794C (en) | 2012-01-03 |
PT1962836E (en) | 2011-03-01 |
ES2357033T3 (en) | 2011-04-15 |
EP1962836B1 (en) | 2010-12-29 |
EP1962836A2 (en) | 2008-09-03 |
CY1112190T1 (en) | 2015-12-09 |
PL1962836T3 (en) | 2011-06-30 |
EP2343068A2 (en) | 2011-07-13 |
AU2010214659B2 (en) | 2012-02-02 |
KR101389184B1 (en) | 2014-04-24 |
CN101365445A (en) | 2009-02-11 |
WO2007056460A3 (en) | 2007-08-23 |
CN105147674A (en) | 2015-12-16 |
JP5044566B2 (en) | 2012-10-10 |
AU2010214659A1 (en) | 2010-09-16 |
AU2006311580A1 (en) | 2007-05-18 |
EP2343068A3 (en) | 2012-06-13 |
SI1962836T1 (en) | 2011-04-29 |
DE602006019311D1 (en) | 2011-02-10 |
KR20080091756A (en) | 2008-10-14 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US5166207A (en) | Method for enhancing the systemic delivery of dextromethorphan for the treatment of neurological disorders | |
US20150093435A1 (en) | Treatment of length dependent neuropathy | |
US20070224253A1 (en) | Transdermal Delivery of Meptazinol | |
AU2011255258B2 (en) | Materials and methods for treatment of inflammation | |
AU2003240113B2 (en) | Formulation of nefopam and its use in the treatment of pain | |
AU2010214659B2 (en) | Treatment of length dependent neuropathy | |
WO2011133212A1 (en) | Methods, compounds and pharmaceutical compositions for treating anxiety and mood disorders | |
Kamibayashi et al. | Alpha-2 adrenergic agonists | |
EP2595617B1 (en) | Topical treatment of neuropathic pain and methods of diagnosis | |
US7973066B2 (en) | Pyrrolo[1,2-A]imidazoledione effective in the treatment of peripheral neurotoxicity induced by chemotherapeutic agents | |
AU2012202326A1 (en) | Treatment of length dependent neuropathy | |
WO2021064589A1 (en) | Intranasal pharmaceutical compositions of cyclobenzaprine | |
US20170348252A1 (en) | Preparation and Use of Ketamine Derivatives and Ketamine Modifiers in the Treatment of Pain | |
US20080255238A1 (en) | Composition containing a thiourea derivative for preventing or treating pruritic or irritant skin diseases | |
US8217068B2 (en) | Compound with anesthetics activity, methods for its production and pharmaceutical compositions comprising the same |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
WWE | Wipo information: entry into national phase |
Ref document number: 200680047961.1 Country of ref document: CN |
|
DPE1 | Request for preliminary examination filed after expiration of 19th month from priority date (pct application filed from 20040101) | ||
ENP | Entry into the national phase |
Ref document number: 2628794 Country of ref document: CA |
|
ENP | Entry into the national phase |
Ref document number: 2008540162 Country of ref document: JP Kind code of ref document: A |
|
WWE | Wipo information: entry into national phase |
Ref document number: 1020087011106 Country of ref document: KR |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2006311580 Country of ref document: AU |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2006837161 Country of ref document: EP |
|
ENP | Entry into the national phase |
Ref document number: 2006311580 Country of ref document: AU Date of ref document: 20061107 Kind code of ref document: A |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 06837161 Country of ref document: EP Kind code of ref document: A2 |